Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
Finch Therapeutics, a clinical-stage microbiome therapeutics company, announced that its CEO, Mark Smith, PhD, will join a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022, at 3:15 pm ET. The event will be accessible via a live webcast on Finch's website, archived for 30 days post-event. Finch is noted for its Human-First Discovery® platform, leading in developing microbiome therapies, including its candidate CP101 for preventing recurrent C. difficile infections, which has received FDA designations.
- None.
- None.
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 3:15 pm ET.
A live webcast of the panel discussion will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
FAQ
What event will Mark Smith from FNCH participate in?
When is the Chardan Metagenomics and Microbiome Medicines Summit?
How can I watch the panel discussion featuring FNCH's CEO?
What is the significance of CP101 for FNCH?
What regulatory designations has FNCH received for CP101?
